NovoCure (NVCR) earnings

Results to: Jun 2026
Latest analysed call: Jun 2026 (Q2 FY26)
Balance sheet to: Dec 2025

Company research is public. Sign in to keep your own companies, notes and cases.

NovoCure earnings: last reported Thu, 23 Jul 2026, for the quarter ended Jun 2026.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

Metric	Value	Change	Basis	Period	Note
Revenue	184 $ million	+15.6% YoY	Quarterly, as filed	Quarter to Jun 2026	Revenue from operations as filed.
Operating margin	-5.8 %	+19.1 pts YoY	Operating profit / revenue	Quarter to Jun 2026	For the quarter; a change is in percentage points.
Net profit	-15.7 $ million	—	Quarterly, as filed	Quarter to Jun 2026	Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown.

Source: Inve data from filed results (SEC filings) · to Jun 2026

Price

$14.68 −2.78% · −$0.42

Last close Oct 23, 2026 · US · USD · Source: Inve

Performance +5.9% 1Y

1Y: $13.86 on 22 Oct 2025 → $14.68. High $19.99 (23 Jul 2026), low $10.03 (9 Feb 2026).

Previous close: $15.1
52-week range: $10.03 – $19.99
One year: +5.46%

Overview

Symbol: NVCR
Sector: Health Care
Exchange: US
Currency: USD

Financials

What the filings say

Net profit, year on year: +61% (quarter to jun 2026 against jun 2025).

In $ million. Oldest period first.

Line item	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026	Jun 2026
Sales	150	155	161	155	159	167	174	184
Operating profit	-34	-32	-63	-38	-40	-36	-67	-11
Operating margin	−22.3%	−20.7%	−39.3%	−24.4%	−24.9%	−21.5%	−38.7%	−5.8%
Profit before tax	-23	-22	-55	-30	-35	-30	-69	-12
Tax rate	−46.8%	−41.6%	−19.4%	−13.3%	−14.8%	−24.1%	−2.7%	−25.8%
Net profit	-33	-31	-66	-34	-40	-37	-71	-16
EPS ($ per share)	-0.31	-0.28	—	-0.31	-0.36	-0.33	-0.62	-0.13

Source: Inve data · income statement, quarterly · to Jun 2026

In $ million. Oldest period first.

Line item	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Equity capital	0	0	0	0	0	0	0	0
Reserves	-644	-651	-631	-686	-778	-986	-1,154	-1,290
Total liabilities	228	262	575	729	750	784	881	464
Fixed assets	8	9	11	23	33	51	78	78
Total assets	340	479	1,052	1,139	1,192	1,146	1,241	804

Source: Inve data · balance sheet · to Dec 2025

In $ million. Oldest period first.

Line item	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from operations	-2	27	99	83	31	-73	-26	-49
Cash from investing	-5	-52	-473	-145	-140	184	-140	437
Cash from financing	69	62	440	26	15	16	90	-451
Net cash flow	62	37	67	-37	-94	127	-76	-63
Capital expenditure	-7	-10	-15	-24	-21	-27	-43	-27
Free cash flow	-9	16	84	59	9	-100	-69	-76

Source: Inve data · cash flow · to Dec 2025

Insider filings

60 filings between Oct 31, 2025 and Jun 30, 2026.

Open market

decisions to buy or sell

Purchases

None

No insider bought shares.

Sales

$3.25M

25 sales by 14 insiders

Compensation

not trading decisions

24: Award — granted as compensation
1: Option exercise — converted options into shares
10: Tax withheld — shares kept back by the company to cover tax

Who traded

open market only

Insider	Bought	Sold	Last filing
DOYLE WILLIAM F	—	$932.9K	Mar 3, 2026
Leonard Frank X	—	$919.8K	Jun 4, 2026
Paravasthu Mukund	—	$694.0K	Mar 5, 2026
Weinberg Uri	—	$232.2K	Mar 4, 2026
Brackmann Christoph	—	$85.3K	Mar 4, 2026
Scannell Timothy J	—	$46.4K	Jun 2, 2026
HILLEMAN JERYL L	—	$46.4K	Jun 2, 2026
LEUNG GABRIEL	—	$46.4K	Jun 2, 2026

Latest filings (50)

Date	Insider	What	Shares	Value
Jun 30, 2026	Leonard Frank X Chief Executive Officer	Award	1,905	$21.2K
Jun 30, 2026	Puri Michal Nath Chief Human Resources Officer	Award	1,905	$21.2K
Jun 30, 2026	Ben Arye Barak General Counsel	Award	1,299	$14.5K
Jun 30, 2026	Danziger Asaf Director	Award	268	$3.0K
Jun 4, 2026	Leonard Frank X Chief Executive Officer	Sale	34,273	$614.6K
Jun 3, 2026	Hung David Director	Award	11,610	$0
Jun 3, 2026	Stafford Kristin Director	Award	11,610	$0
Jun 3, 2026	Madden Martin J. Director	Award	11,610	$0
Jun 3, 2026	LEUNG GABRIEL Director	Award	11,610	$0
Jun 3, 2026	Ocean Allyson J Director	Award	11,610	$0
Jun 3, 2026	HILLEMAN JERYL L Director	Award	11,610	$0
Jun 3, 2026	Scannell Timothy J Director	Award	11,610	$0
Jun 3, 2026	VERNON W ANTHONY Director	Award	11,610	$0
Jun 2, 2026	Hung David Director	Sale	2,945	$46.4K
Jun 2, 2026	LEUNG GABRIEL Director	Sale	2,945	$46.4K
Jun 2, 2026	Stafford Kristin Director	Sale	2,945	$46.4K
Jun 2, 2026	HILLEMAN JERYL L Director	Sale	2,945	$46.4K
Jun 2, 2026	Ocean Allyson J Director	Sale	2,945	$46.4K
Jun 2, 2026	Scannell Timothy J Director	Sale	2,945	$46.4K
Jun 2, 2026	VERNON W ANTHONY Director	Sale	2,945	$46.4K
Apr 28, 2026	VERNON W ANTHONY Director	Option exercise	21,500	$244.9K
Mar 5, 2026	Paravasthu Mukund Chief Operating Officer	Sale	43,246	$595.7K
Mar 4, 2026	Leonard Frank X Chief Executive Officer	Sale	5,607	$74.6K
Mar 4, 2026	Cordova Ashley Former Chief Executive Officer	Tax withheld	17,638	$234.6K
Mar 4, 2026	Weinberg Uri Chf Medical and Innovation Ofr	Sale	6,412	$85.3K
Mar 4, 2026	Brackmann Christoph Chief Financial Officer	Sale	6,412	$85.3K
Mar 4, 2026	Paravasthu Mukund Chief Operating Officer	Sale	5,377	$71.5K
Mar 4, 2026	Leupin Nicolas Former Chief Medical Officer	Sale	1,100	$14.6K
Mar 4, 2026	Puri Michal Nath Chief Human Resources Officer	Sale	1,100	$14.6K
Mar 3, 2026	Ben Arye Barak General Counsel	Award	50,125	$0
Mar 3, 2026	Leonard Frank X Chief Executive Officer	Award	150,000	$0
Mar 3, 2026	Weinberg Uri Chf Medical and Innovation Ofr	Award	50,125	$0
Mar 3, 2026	DOYLE WILLIAM F Executive Chairman	Sale	50,557	$646.4K
Mar 3, 2026	DOYLE WILLIAM F Executive Chairman	Sale	21,330	$286.4K
Mar 3, 2026	DOYLE WILLIAM F Executive Chairman	Award	200,284	$0
Mar 3, 2026	DOYLE WILLIAM F Executive Chairman	Award	200,000	$0
Mar 3, 2026	Brackmann Christoph Chief Financial Officer	Award	55,137	$0
Mar 3, 2026	Paravasthu Mukund Chief Operating Officer	Award	45,112	$0
Mar 3, 2026	Puri Michal Nath Chief Human Resources Officer	Award	40,100	$0
Mar 2, 2026	Leonard Frank X Chief Executive Officer	Sale	7,232	$97.6K
Mar 2, 2026	Cordova Ashley Former Chief Executive Officer	Tax withheld	2,410	$32.9K
Mar 2, 2026	Paravasthu Mukund Chief Operating Officer	Sale	408	$5.5K
Mar 2, 2026	Weinberg Uri Chf Medical and Innovation Ofr	Sale	3,272	$43.6K
Mar 2, 2026	Cordova Ashley Former Chief Executive Officer	Tax withheld	7,228	$98.8K
Feb 28, 2026	Ben Arye Barak General Counsel	Award	17,755	$0
Feb 28, 2026	Cordova Ashley Former Chief Executive Officer	Award	23,818	$0
Feb 28, 2026	Weinberg Uri Chf Medical and Innovation Ofr	Award	12,992	$0
Feb 28, 2026	Leonard Frank X Chief Executive Officer	Award	18,621	$0
Feb 27, 2026	Leonard Frank X Chief Executive Officer	Sale	9,734	$133.0K
Feb 27, 2026	Cordova Ashley Former Chief Executive Officer	Tax withheld	11,541	$158.7K

Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.

Your own record

Start an Inve Case for NovoCure Ltd

Free account. Everything above stays public.

Write why you follow NovoCure Ltd and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading